WINTON GROUP Ltd Makes New $603,000 Investment in GSK PLC Sponsored ADR $GSK

WINTON GROUP Ltd purchased a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) in the 2nd quarter, HoldingsChannel reports. The firm purchased 11,500 shares of the pharmaceutical company’s stock, valued at approximately $603,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Elyxium Wealth LLC purchased a new position in shares of GSK in the fourth quarter worth about $30,000. Trust Co. of Vermont purchased a new stake in GSK during the 2nd quarter valued at about $54,000. Philadelphia Investment Partners LLC purchased a new stake in GSK during the 2nd quarter valued at about $70,000. Ancora Advisors LLC bought a new position in GSK during the 2nd quarter worth approximately $71,000. Finally, Bogart Wealth LLC grew its position in GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after acquiring an additional 200 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Berenberg upgraded GSK from “hold” to “buy,” citing an improved growth outlook. The endorsement may support sentiment by highlighting potential value in GSK’s pipeline and earnings prospects. GSK upgraded at Berenberg on growth outlook
• Positive Sentiment: GSK agreed to acquire global rights to an experimental trispecific T-cell engager from Chimagen Biosciences for up to $750 million. The multiple myeloma therapy expands GSK’s oncology portfolio and could add a differentiated asset, although its value depends on clinical and regulatory success. GSK strikes up to $750 million deal for cancer-targeting drug
• Positive Sentiment: Encouraging lung-cancer data strengthened GSK’s oncology investment case. Jideytro showed high response rates and durable disease control in first-line ROS1-positive non-small-cell lung cancer, supporting plans for an expanded U.S. filing. Separately, GSK reported positive Phase III survival data for its antibody-drug conjugate in relapsed small-cell lung cancer. These results could broaden the commercial opportunity for the company’s oncology pipeline. GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, GSK discussed its business and pipeline strategy. The presentation may provide additional context for investors, but no specific new financial guidance was identified in the available report. GSK Presents at Morgan Stanley Healthcare Conference
• Negative Sentiment: GSK plans to close its Dresden, Germany, vaccine manufacturing site by summer 2027, putting 641 jobs at risk. The move reflects weaker demand for traditional egg-based flu vaccines and excess manufacturing capacity. While the restructuring could improve long-term efficiency, it highlights pressure in the vaccine business and may create near-term costs. GSK Cuts 641 Jobs in Vaccine Manufacturing Restructuring

Analyst Ratings Changes

GSK has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Thursday, July 30th. Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Berenberg Bank set a $60.00 target price on shares of GSK in a report on Tuesday. Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Morgan Stanley reiterated an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $56.50.

GSK Stock Down 0.1%

GSK stock opened at $50.01 on Wednesday. The company has a market cap of $101.15 billion, a price-to-earnings ratio of 15.64, a P/E/G ratio of 2.10 and a beta of 0.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The business’s 50-day moving average is $51.16 and its two-hundred day moving average is $52.62. GSK PLC Sponsored ADR has a fifty-two week low of $39.29 and a fifty-two week high of $61.69.

GSK (NYSE:GSK) last released its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%.The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. During the same period in the previous year, the company posted $0.47 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts forecast that GSK PLC Sponsored ADR will post 4.81 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be issued a $0.4515 dividend. The ex-dividend date of this dividend is Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.6%. GSK’s payout ratio is 55.63%.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.